Full history for every metric is available with a Kvantra account
YanAn Bicon Pharmaceutical Listed Company (002411.SZ)
Key financial summary
Financials in CNY| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | 5,368 | 8,447 | 9,328 | 6,940 | 7,663 | 8,106 | 7,058 |
| Operating profit | CNY m | 343 | -1,720 | |||||
| Net profit | CNY m | 893 | 404 | 355 | -1,073 | -660 | -1,055 | -1,561 |
| EPS reported | CNY | -0.66 | -0.98 | |||||
| Operating cashflow per share | CNY | 1.83 | 1.83 | |||||
| Capex per share | CNY | 0.91 | 0.91 | |||||
| FCF per share | CNY | 0.92 | 0.92 | |||||
| Free cash flow | CNY m | 1,472 | -3,059 | |||||
| Net debt | CNY m | 835 | 1,207 | |||||
| Book value equity | CNY m | 5,773 | 5,625 | |||||
| Book value per share | CNY | 3.61 | 3.67 | |||||
| Number of shares | m | 1,600.46 | 1,531.69 | |||||
| DPS (TTM paid) | CNY | 1.26 | 0.00 |
Financial summary
Financials in CNY| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.93 | 0.17 | |||||
| P/S LTM | x | 1.37 | 0.13 | |||||
| P/FCF LTM | x | 7.57 | -0.31 | |||||
| EV/EBITDA LTM | x | -11.76 | -7.95 | |||||
| EV/Sales LTM | x | 1.49 | 0.31 | |||||
| Earnings Yield LTM | % | -9.47% | -106.29% | |||||
| FCF Yield | % | 13.22% | -322.01% | |||||
| Quality | ||||||||
| ROE | % | -18.27% | -15.74% | |||||
| ROIC | % | 2.60% | 2.60% | |||||
| Operating margin | % | 4.23% | 4.23% | |||||
| Gross margin | % | 25.06% | 25.06% | |||||
| FCF/Sales | % | 18.16% | 18.16% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +5.78% | -16.76% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | +359.71% | - | |||||
| Operating Profit Growth | % | -71.89% | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 18.15% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | -191.66% | -134.80% | |||||
| FCF/Debt | x | 0.82 | -1.72 | |||||
| Net Debt/EBITDA | x | -0.89 | -0.89 | |||||
| EBIT/Net interest | x | 1.21 | 1.21 | |||||
| Net debt/market cap | % | 7.49% | 127.01% | |||||
| Net debt/Equity | x | 0.14 | 0.21 | |||||
| Gross debt/equity | x | 0.31 | 0.32 | |||||
Company overview
YanAn Bicon Pharmaceutical Listed Company operates as a Chinese entity focused on the entire lifecycle—from research and development to production and distribution—of pharmaceutical intermediates, pesticide intermediates, and advanced energy and materials products. Its product portfolio features medical goods sold under the "Bikangweizheng" and "DoctorBaby" brand names. The company's product offerings include lithium hexafluorophosphate, a key constituent for lithium-ion battery electrolytes. Beyond this, it manufactures and supplies various high-performance composite materials. These composite materials are integral to numerous applications, including but not limited to cut-resistant gloves, home textile items, cables, fishing nets, outdoor sportswear, bulletproof helmets, stab-resistant clothing, as well as components for military and aerospace industries, ocean-going vessels, naval ship ropes, deep-sea fishing trawls, anti-wind wave cages, sporting equipment, and construction engineering reinforcement. Among its pharmaceutical intermediates are triclopyridine sodium, 5,5-dimethylhydantoin, and benzaldehyde. Established in 2007 and headquartered in Xi'an, China, the company underwent a name change in October 2018. Previously known as JiangSu Bicon Pharmaceutical Listed Company, it adopted its current designation, YanAn Bicon Pharmaceutical Listed Company. It was formerly an affiliate of Xinyi Bicon New Medicine Industry Complex Investment Co., Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
YanAn Bicon Pharmaceutical Listed Company (002411.SZ)
YanAn Bicon Pharmaceutical Listed Company operates as a Chinese entity focused on the entire lifecycle—from research and development to production and distribution—of pharmaceutical intermediates, pesticide intermediates, and advanced energy and materials products. Its product portfolio features medical goods sold under the "Bikangweizheng" and "DoctorBaby" brand names. The company's product offerings include lithium hexafluorophosphate, a key constituent for lithium-ion battery electrolytes. Beyond this, it manufactures and supplies various high-performance composite materials. These composite materials are integral to numerous applications, including but not limited to cut-resistant gloves, home textile items, cables, fishing nets, outdoor sportswear, bulletproof helmets, stab-resistant clothing, as well as components for military and aerospace industries, ocean-going vessels, naval ship ropes, deep-sea fishing trawls, anti-wind wave cages, sporting equipment, and construction engineering reinforcement. Among its pharmaceutical intermediates are triclopyridine sodium, 5,5-dimethylhydantoin, and benzaldehyde. Established in 2007 and headquartered in Xi'an, China, the company underwent a name change in October 2018. Previously known as JiangSu Bicon Pharmaceutical Listed Company, it adopted its current designation, YanAn Bicon Pharmaceutical Listed Company. It was formerly an affiliate of Xinyi Bicon New Medicine Industry Complex Investment Co., Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free